12.19.2017
Prevent & Delay
$420,804.00
36 months
Creating type 1 diabetes-specific chimeric antigen receptors for regulatory T cells as a therapy for type 1 diabetes
Funds support a work into a preclinical proof-of-principle for an engineered targeted Treg cell therapy to treat type 1 diabetes.